ATE106886T1 - Azabicycloamide und -ester als 5-ht3-receptor- antagonisten. - Google Patents

Azabicycloamide und -ester als 5-ht3-receptor- antagonisten.

Info

Publication number: ATE106886T1
Authority: AT; Austria
Prior art keywords: esters; azabicycloamides; receptor antagonists; antagonists; receptor
Prior art date: 1989-11-17

Application number

AT90312218T

Other languages

English (en)

Inventor

Terry Jay Rosen

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-11-17

Filing date

1990-11-08

Publication date

1994-06-15

1990-11-08 Application filed by Pfizer filed Critical Pfizer

1994-06-15 Application granted granted Critical

1994-06-15 Publication of ATE106886T1 publication Critical patent/ATE106886T1/de

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Hospice & Palliative Care (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Otolaryngology (AREA)
Anesthesiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

AT90312218T 1989-11-17 1990-11-08 Azabicycloamide und -ester als 5-ht3-receptor- antagonisten. ATE106886T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
PCT/US1989/005097 WO1991007402A1 (en)	1989-11-17	1989-11-17	Azabicyclo amides and esters as 5-ht3 receptor antagonists

Publications (1)

Publication Number	Publication Date
ATE106886T1 true ATE106886T1 (de)	1994-06-15

Family

ID=22215354

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT90312218T ATE106886T1 (de)	1989-11-17	1990-11-08	Azabicycloamide und -ester als 5-ht3-receptor- antagonisten.

Country Status (11)

Country	Link
EP (1)	EP0434202B1 (de)
JP (1)	JPH0699428B2 (de)
AT (1)	ATE106886T1 (de)
CA (1)	CA2030077C (de)
DE (1)	DE69009715T2 (de)
DK (1)	DK0434202T3 (de)
ES (1)	ES2055344T3 (de)
FI (1)	FI922124A0 (de)
IE (1)	IE63420B1 (de)
PT (1)	PT95895A (de)
WO (1)	WO1991007402A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9027111D0 (en) *	1990-12-13	1991-02-06	Raychem Ltd	Circuit protection device
GB9214184D0 (en) *	1992-07-03	1992-08-12	Smithkline Beecham Plc	Pharmaceuticals
FR2699533A1 (fr) *	1992-12-21	1994-06-24	Mouhtaram Mohamed	Dérivés de N-((1,4-dialkyl-6-arylpipérazine-2-yl)méthyl)benzamides. (Isomères cis et trans) Propriétés pharmacologiques et applications.
BRPI0517494A (pt) *	2004-12-22	2008-10-14	Memory Pharm Corp	composto, composição farmacêutica, método de ativação/estimulação seletiva de receptores nicotìnicos de a-7 em um paciente em que tal ativação/estimulação tem um efeito terapêutico, método de tratamento de um paciente que sofre de uma doença psicótica, uma doença neurodegenerativa que envolve uma disfunção do sistema colinérgico, e/ou uma condição de debilitação da memória e/ou da cognição, método de tratamento de um paciente que sofre de demência e/ou uma outra condição com perda da memória, método de tratamento de um paciente que sofre de debilitação da memória devido à debilitação cognitiva suave devido ao envelhecimento, mal de alzheimer, esquizofrenia, mal de parkinson, mal de huntington, mal de pick, mal de creutzfeldt-jakob, depressão, envelhecimento, trauma na cabeça, acidente vascular cerebral, hipoxia do snc, senilidade cerebral, demência de multiinfarto, hiv e/ou doença cardiovascular, método de tratamento e/ou prevenção da demência em um paciente com o mal de alzheimer, método de tratamento de um paciente para cortar o vìcio do álcool ou o tratamento de um paciente com a terapia anti-intoxicação, método de tratamento de um paciente para propiciar neuroproteção contra os danos associados com acidentes vasculares cerebrais e isquemia e excitotoxicidade induzida por glutamatos, método de tratamento de um paciente que sofre do vìcio da nicotina, dor, tontura do fuso horário, obesidade e/ou diabetes, método de indução do ato de parar fumar em um paciente, método de tratamento de um paciente que sofre de debilitação cognitiva suave (mci), demência vascular (vad), declìnio cognitivo associado com a idade (aacd), amnésia associada com a cirurgia com o coração aberto, parada cardìaca, anestesia geral, deficiências da memória devido à exposição a agentes anestésicos, debilitação cognitiva induzida pela privação do sono, sìndrome de fadiga crÈnica, narcolepsia, demência relacionada com a aids, debilitação cognitiva relacionada com a epilepsia, sìndrome de down, demência relacionada ao alcoolismo, debilitações da memória induzidas por drogas/substáncias, demência pugilìstica (sìndrome do boxeador), ou demência animal, método para o tratamento da perda da memória, método para o tratamento de um paciente que sofre de debilitação da memória, método para o tratamento ou a profilaxia de uma doença ou de uma condição resultante da disfunção da transmissão do receptor nicotìnico de acetilcolina em um paciente, método para o tratamento ou a profilaxia de uma doença ou de uma condição resultante de receptores nicotìnicos de acetilcolina defeituosos ou funcionando mal em um paciente, método para o tratamento ou a profilaxia de uma doença ou de uma condição resultante da transmissão suprimida do receptor nicotìnico de acetilcolina em um paciente, método para o tratamento ou a profilaxia de uma doença ou de uma condição resultante da perda de sinapses colinérgicas em um paciente, método para a proteção dos neurÈnios em um paciente com neurotoxicidade induzi

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3405134A (en) *	1965-08-17	1968-10-08	Colgate Palmolive Co	Quinuclidyl esters of aromatic acids
US4467095A (en) *	1969-02-10	1984-08-21	Fmc Corporation	Anticholinergic compounds
US3563995A (en) *	1969-04-17	1971-02-16	Ian Wellings	Alkyl esters of 1-azabicyclo(2.2.2)oct-2-ene-3-(4 - chloro-3-sulfamoylanilino)-2-carboxylic acid
GB1293446A (en) *	1970-07-23	1972-10-18	Rech S Et D Applic Scient Soge	Quinuclidine derivatives, the preparation thereof and pharmaceutical compositions containing them
FR2531955A1 (fr) *	1982-08-17	1984-02-24	Pharmuka Lab	Nouveau procede de preparation de derives de la quinuclidine substitues en position 3
CH667657A5 (de) *	1985-01-07	1988-10-31	Sandoz Ag	Carbocyclische und heterocyclische carbonylmethylen- und methylpiperidine und -pyrrolidine.
GB8525844D0 (en) *	1985-10-19	1985-11-20	Beecham Group Plc	Compounds
EP0311724A1 (de) *	1987-10-16	1989-04-19	Synthelabo	Anxiolytische R-N-(1-Azabicyclo[2.2.2]oct-3-yl)-benzamide und -thiobenzamide

1989
- 1989-11-17 FI FI922124A patent/FI922124A0/fi not_active Application Discontinuation
- 1989-11-17 WO PCT/US1989/005097 patent/WO1991007402A1/en not_active Ceased
1990
- 1990-11-08 DK DK90312218.2T patent/DK0434202T3/da active
- 1990-11-08 DE DE69009715T patent/DE69009715T2/de not_active Expired - Fee Related
- 1990-11-08 EP EP90312218A patent/EP0434202B1/de not_active Expired - Lifetime
- 1990-11-08 ES ES90312218T patent/ES2055344T3/es not_active Expired - Lifetime
- 1990-11-08 AT AT90312218T patent/ATE106886T1/de active
- 1990-11-15 CA CA002030077A patent/CA2030077C/en not_active Expired - Fee Related
- 1990-11-15 PT PT95895A patent/PT95895A/pt not_active Application Discontinuation
- 1990-11-16 JP JP31124190A patent/JPH0699428B2/ja not_active Expired - Lifetime
- 1990-11-16 IE IE413490A patent/IE63420B1/en not_active IP Right Cessation

Also Published As

Publication number	Publication date
JPH03170480A (ja)	1991-07-24
FI922124A7 (fi)	1992-05-11
DK0434202T3 (da)	1994-07-04
ES2055344T3 (es)	1994-08-16
PT95895A (pt)	1991-09-13
DE69009715T2 (de)	1994-09-22
WO1991007402A1 (en)	1991-05-30
IE63420B1 (en)	1995-04-19
CA2030077C (en)	1995-08-22
FI922124L (fi)	1992-05-11
CA2030077A1 (en)	1991-05-18
JPH0699428B2 (ja)	1994-12-07
DE69009715D1 (de)	1994-07-14
IE904134A1 (en)	1991-05-22
EP0434202B1 (de)	1994-06-08
FI922124A0 (fi)	1992-05-11
EP0434202A1 (de)	1991-06-26

Publication	Publication Date	Title
DE69127791D1 (de)	1997-11-06	Diazabicyclononyl-Derivate als 5-HT3 Rezeptor Antagonisten
FI914533A7 (fi)	1992-03-28	Fibrinogeenireseptoriantagonisteja
SE8303651L (sv)	1983-12-30	Bensoesyrapiperidylesterderivat
NO921182D0 (no)	1992-03-26	Piperidinderivater
FI914535A7 (fi)	1992-03-28	Uusia fibrinogeenireseptoriantagonisteja
DE3476204D1 (de)	1989-02-23	N-(bicyclic heterocyclyl)-4-piperidinamines
FI905022A7 (fi)	1991-04-14	Fibrinogeenin reseptorin antagonisteja
NO964236D0 (no)	1996-10-04	Anvendelse av serotonin-antagonister (5HT3) for behandling av fibromyalgi
DE69207351D1 (de)	1996-02-15	Fibrinogen-Rezeptor-Antagoniste
FI934894A7 (fi)	1993-11-05	Fibrinogeenireseptorin antagonisteja
MX9101311A (es)	1992-05-04	Antagonistas receptores de fibrinogeno
FI905023A7 (fi)	1991-04-14	Fibrinogeenin reseptorin antagonisteja
EP0698023A4 (de)	1997-07-02	Antagonisten des fibrinogenrezeptors
NO844755L (no)	1985-05-31	Bicykliske heterocyklyholdige n-(bicykliske heterocyklyl)-4-piperidinaminer
FI911083A7 (fi)	1991-09-07	Menetelmä kolinergisina aineina käyttökelpoisten 1-atsabisyklo/2.2.1/heptaani- tai -/2.2.2/oktaani-3-oni-O-oksiimien valmistamiseksi
DE69022553D1 (de)	1995-10-26	Vorrichtung zum Unterdrücken von Spannungsschwankungen und Oberschwingungen.
DE69012867D1 (de)	1994-11-03	Direktanlernbarer Roboter.
FI953916L (fi)	1995-08-21	Fibrinogeenireseptoriantagonisteja
ATE198202T1 (de)	2001-01-15	Fibrinogen receptor antagonisten
DE69009715D1 (de)	1994-07-14	Azabicycloamide und -ester als 5-HT3-Receptor-Antagonisten.
FI891473A0 (fi)	1989-03-28	Menetelmä terapeuttisesti käyttökelpoisten 4-aryyli-4-piperidiinikarbinolien valmistamiseksi
ATE181257T1 (de)	1999-07-15	Testbesteck
DE69328701D1 (de)	2000-06-29	Diazabicycloderivate als 5-HT3-Antagonisten
FI892051A0 (fi)	1989-04-28	Foerfarande foer framstaellning av 5-klor-3-klorsulfonyl-2-tiofencarbonsyraestrar.
FI913835A0 (fi)	1991-08-13	6-substituerade-tetrahydrobenz(cd) indoler.